ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients

Frontiers in Genetics

Volumn 3, Issue NOV, 2012, Pages

  Swart, Marelize ^a   Ren, Yuan ^a   Smith, Peter ^a   Dandara, Collet ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

ABCB1; Efavirenz; HIV AIDS; Pharmacogenetics; South Africa

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84876108975     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00236     Document Type: Article

References (31)

1. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman,M. M. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol Toxicol. 39, 361-398.
2. Ameyaw, M. M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., et al. (2001). MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 11, 217-221.
3. Anglicheau, D., Thervet, E., Etienne, I., Hurault De Ligny, B., Le Meur, Y., Touchard, G., et al. (2004). CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 75, 422-433.
4. Bodor, M., Kelly, E. J., and Ho, R. J. (2005). Characterization of the human MDR1 gene. AAPS J. 7, E1-E5.
5. Brown, K. C., Hosseinipour, M. C., Hoskins, J. M., Thirumaran, R. K., Tien,H. C., Weigel, R., et al. (2011). Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 13, 113-121.
6. Cascorbi, I. (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 112, 457-473.
7. Cascorbi, I., Gerloff, T., Johne, A., Meisel, C., Hoffmeyer, S., Schwab, M., et al. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69,169-174.
8. Chi, J., Jayewardene, A. L., Stone, J. A., Motoya, T., and Aweeka, E T. (2002). Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir, and amprenavir in human plasma by LC/MS/MS. J. Pharm. Biomed. Anal. 30,675-684.
9. Dandara, C., Lombard, Z., Du Plooy, I., Mclellan, T., Norris, S. A., and Ramsay, M. (2011). Genetic variants in CYP (-1A2,-2C9,-2C19,-3A4, and-3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics 12, 1663-1670.
10. Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P., et al. (2002). Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359, 30-36.
11. Fung, K. L., and Gottesman, M. M. (2009). A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 1794, 860-871.
12. Gow, J. M., Hodges, L. M., Chinn, L. W., and Kroetz, D. L. (2008). Substrate-dependent effects of human ABCB1 coding polymorphisms. J. Pharmacol. Exp. Ther. 325, 435-442.
13. Gu, W., Zhou, T., Ma, J., Sun, X., and Lu, Z. (2004). The relationship between synonymous codon usage and protein structure in Escherichia coli and Homo sapiens. BioSystems 73, 89-97.
14. Gustafson, S., Proper, J. A., Bowie, E. J., and Sommer, S. S. (1987).Parameters affecting the yield of DNA from human blood. Anal. Biochem. 165,294-299.
15. Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbe, L., et al. (2005). Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult aids clinical trials group study. J. Infect. Dis. 192,1931-1942.
16. Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., et al. (2004). The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154.
17. Ikediobi, O., Aouizerat, B., Xiao, Y., Gandhi, M., Gebhardt, S., and Warnich, L. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Hum. Genomics 5,265-282.
18. Kuzuya, T., Kobayashi, T., Moriyama, N., Nagasaka, T., Yokoyama, I., Uchida, K.,et al. (2003).Amlodipine,butnot MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 76, 865-868.
19. Leschziner, G. D., Andrew, T., Pirmohamed, M., and Johnson, M. R. (2007). ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7, 154-179.
20. Lubomirov, R., Colombo, S., Di Iulio, J., Ledergerber, B., Martinez, R., Cavassini, M., et al. (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J. Infect. Dis. 203, 246-257.
21. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., and Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71-75.
22. Meissner, K., Jedlitschky, G., Meyer Zu Schwabedissen, H., Dazert, P., Eckel, L., Vogelgesang, S., et al. (2004). Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14,381-385.
23. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., d'Arminio Monforte, A., et al. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362, 22-29.
24. Motsinger, A. A., Ritchie, M. D., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbe, L., et al. (2006). Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genomics 16, 837-845.
25. Mukonzo, J. K., Roshammar, D., Waako, P., Andersson, M., Fukasawa, T., Milani, L., et al. (2009). A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68, 690-699.
26. Rhodes, K. E., Zhang, W., Yang, D., Press, O. A., Gordon, M., Vallbohmer, D., et al. (2007). ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab. Lett. 1, 23-30.
27. Schwab, M., Eichelbaum, M., and Fromm, M. F. (2003). Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43, 285-307.
28. Stephens, M., and Donnelly, P. (2003). A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162-1169.
29. Stephens, M., and Scheet, P. (2005). Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76, 449-462.
30. Stephens, M., Smith, N. J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989.
31. Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., et al. (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66, 2092-2098.